Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Z<sub>HER2:V2</sub>-pemetrexed conjugate could inhibit tumor growth of HER2-positive lung adenocarcinoma and may have the potential to become a targeted drug for lung cancer.
|
30578135 |
2020 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We examined changes in CTC numbers and morphology early after targeting therapy in EGFR-mutated PC-9 human lung cancer and HER2-gene amplified GLM-1 gastric cancer mouse CTC models using a cytology-based semi-automated CTC detection platform.
|
31519570 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
To assess antigen reactivity, <sup>89</sup>Zr-DFO-trastuzumab was evaluated using the Lindmo method and tested in PET/CT imaging of mouse models of human epidermal growth factor receptor 2-positive or -negative lung cancer.
|
30442753 |
2019 |
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
No EGFR mutations were detected in BC tissue and no HER2 expression was detected in LC samples.
|
30799393 |
2019 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.
|
30685684 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Germline mutations in EGFR and erb-b2 receptor tyrosine kinase 2 (ERBB2) have been previously reported in lung cancers that may be associated with genetic susceptibility to lung cancer.
|
30610926 |
2019 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The variable responses to anti-HER2 therapies in these patients prompt us to examine impact of <i>HER2</i> variants and co-mutations on responses to anti-HER2 treatments in lung cancer.
|
31748336 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overlapping with ERBB2-associated human lung cancer genes further identified those ERBB2 downstream players potentially conserved in human and mouse lung tumors.
|
31248101 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data provide a framework for brain imaging surveillance in patients with HER2-mutant lung cancers and underpin the need to develop HER2-targeted agents with central nervous system activity.
|
31469421 |
2019 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We assessed the activity of ado-trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in a cohort of patients with HER2-mutant lung cancers as part of a phase II basket trial.
|
29989854 |
2018 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study involves ligand-based pharmacophore modeling of various kinases, including EGFR (T790 M), cMET, ErbB2, FGFR and ALK, which are well established targets of normal as well resistant lung cancer.
|
30343450 |
2018 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
|
29532558 |
2018 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among patients with HER2-mutant lung cancers, 25 received pemetrexed-based first line chemotherapy.
|
29587667 |
2018 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The Lung Cancer Mutation Consortium (LCMC) is a multi-institutional effort to identify and treat oncogenic driver events in patients with lung adenocarcinomas.<b>Experimental Design:</b> Sixteen U.S. institutions enrolled 1,367 patients with lung cancer in LCMC2; 904 were deemed eligible and had at least one of 14 cancer-related genes profiled using validated methods including genotyping, massively parallel sequencing, and IHC.<b>Results:</b> The use of targeted therapies in patients with <i>EGFR, ERBB2,</i> or <i>BRAF</i> p.V600E mutations, <i>ALK, ROS1</i>, or <i>RET</i> rearrangements, or <i>MET</i> amplification was associated with a survival increment of 1.5 years compared with those with such mutations not receiving targeted therapy, and 1.0 year compared with those lacking a targetable driver.
|
29217530 |
2018 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This is the first radiogenomics study of HER2 mutations in lung cancer.
|
29906786 |
2018 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Results suggested that the conjugate exhibited selective antiproliferative activity in HER2-overexpressing breast and lung cancer cell lines and was able to block HER2:HER3 heterodimerization.
|
30314880 |
2018 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
|
30527195 |
2018 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PI3KCA activating mutations were associated with ERBB2 mutations in 12.4% of cases mainly in breast and lung cancer.
|
29941010 |
2018 |
Malignant neoplasm of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Among these, a symmetrical cyclic peptidomimetic (compound 18) exhibited antiproliferative activity in HER2-overexpressing lung cancer cell lines with IC<sub>50</sub> values in the nanomolar concentration range.
|
29436155 |
2018 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Activating EGFR mutations, HER2, and HER3 are implicated in lung cancer; however, with the exception of EGFR gene amplification in lung adenocarcinoma harboring EGFR mutations, their involvement in disease progression during the early stages is poorly understood.
|
29473311 |
2018 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Consistent with this, a G660D germline mutant lung cancer patient showed remarkable clinical response to HER2 blockade.
|
30449325 |
2018 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In contrast, afatinib and neratinib were predicted to be more effective than other inhibitors for the A775_776insYVMA mutation, the most frequent <i>ERBB2</i> mutation in lung cancer.
|
29967253 |
2018 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The peptidomimetic (Cyclo(1,10)PpR (<i>R</i>) Anapa-FDDF-(<i>R</i>)-Anapa)R, compound 18) was shown to exhibit antiproliferative activity with an IC<sub>50</sub> of 194 nM in HER2-expressing breast cancer cell lines and 18 nM in lung cancer cell lines.
|
29088782 |
2017 |
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
This trial will provide information on whether T-DM1 monotherapy is effective against HER2+ lung cancer.
|
27497829 |
2017 |
Malignant neoplasm of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Highly sensitive detection of a HER2 12-base pair duplicated insertion mutation in lung cancer using the Eprobe-PCR method.
|
28152008 |
2017 |